Your browser doesn't support javascript.
loading
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report.
Williams, Kirsten M; Inamoto, Yoshihiro; Im, Annie; Hamilton, Betty; Koreth, John; Arora, Mukta; Pusic, Iskra; Mays, Jacqueline W; Carpenter, Paul A; Luznik, Leo; Reddy, Pavan; Ritz, Jerome; Greinix, Hildegard; Paczesny, Sophie; Blazar, Bruce R; Pidala, Joseph; Cutler, Corey; Wolff, Daniel; Schultz, Kirk R; Pavletic, Steven Z; Lee, Stephanie J; Martin, Paul J; Socie, Gerard; Sarantopoulos, Stefanie.
Afiliação
  • Williams KM; Division of Blood and Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
  • Inamoto Y; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Im A; Division of Hematology Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Hamilton B; Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Koreth J; Dana-Farber Cancer Institute, Division of Hematologic Malignancies, Harvard Medical School, Boston, Massachusetts.
  • Arora M; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
  • Pusic I; BMT and Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Mays JW; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
  • Carpenter PA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Luznik L; Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Reddy P; Divsion of Hematology and Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.
  • Ritz J; Dana-Farber Cancer Institute, Division of Hematologic Malignancies, Harvard Medical School, Boston, Massachusetts.
  • Greinix H; Clinical Division of Hematology, Medical University of Graz, Graz, Austria.
  • Paczesny S; Department of Microbiology and Immunology and Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina.
  • Blazar BR; Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
  • Pidala J; Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Cutler C; Dana-Farber Cancer Institute, Division of Hematologic Malignancies, Harvard Medical School, Boston, Massachusetts.
  • Wolff D; Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany.
  • Schultz KR; Pediatric Oncology, Hematology, and Bone Marrow Transplant, BC Children's Hospital, Vancouver, British Columbia, Canada.
  • Pavletic SZ; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
  • Martin PJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
  • Socie G; Hematology Transplantation, Saint Louis Hospital, AP-HP, and University of Paris, INSERM U976, Paris, France. Electronic address: Gerard.socie@aphp.fr.
  • Sarantopoulos S; Division of Hematological Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute, Durham, North Carolina. Electronic address: Stefanie.sarantopoulos@duke.edu.
Transplant Cell Ther ; 27(6): 452-466, 2021 06.
Article em En | MEDLINE | ID: mdl-33877965
ABSTRACT
Preventing chronic graft-versus-host disease (GVHD) remains challenging because the unique cellular and molecular pathways that incite chronic GVHD are poorly understood. One major point of intervention for potential prevention of chronic GVHD occurs at the time of transplantation when acute donor anti-recipient immune responses first set the events in motion that result in chronic GVHD. After transplantation, additional insults causing tissue injury can incite aberrant immune responses and loss of tolerance, further contributing to chronic GVHD. Points of intervention are actively being identified so that chronic GVHD initiation pathways can be targeted without affecting immune function. The major objective in the field is to continue basic studies and to translate what is learned about etiopathology to develop targeted prevention strategies that decrease the risk of morbid chronic GVHD without increasing the risks of cancer relapse or infection. Development of strategies to predict the risk of developing debilitating or deadly chronic GVHD is a high research priority. This working group recommends further interrogation into the mechanisms underpinning chronic GVHD development, and we highlight considerations for future trial design in prevention trials.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Geórgia

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Geórgia